At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating CF101 1mg, CF101 2mg, and 2 other interventions for Plaque Psoriasis. Completed, enrolled 76 participants across 4 sites.
Detailed Summary
This study will test the hypothesis that CF101, which is under development to treat other immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of chronic plaque psoriasis. Patients with psoriasis who qualify for the study will be treated every 12 hours (q12h) with CF101 capsules, or placebo capsules, for 12 weeks. The safety of treatment will be carefully assessed through clinical and laboratory monitoring. The effect of treatment on psoriasis will be evaluated through standard techniques of examination and measurement of the severity of skin involvement.
Study Details
Timeline
Interventions
CF101 1 mg q12 hours for 12 weeks
CF101 2 mg q12 hours for 12 weeks
CF101 4 mg q12 hours for 12 weeks
Placebo tablets q12 hours for 12 weeks